Transcutaneous Tibial Nerve Stimulation Therapy in Children With Overactive Bladder

Inclusion Criteria

• •1. Diagnosed with OAB according to the "Chinese Urology and Male Disease Diagnosis and Treatment Guidelines" 2022 edition;
• •2. Age between 6 and 18 years, gender unrestricted;
• •3. Need to receive and consent to TTNS treatment for medical reasons;
• •4. Urination diary (3 days prior to random enrollment) shows an average of ≥8 urination times per 24 hours;
• •5. The patient or their representative understands the purpose and requirements of this study and signs the informed consent form (if the subject is \<8 years old, written consent from the legal guardian is required; if the subject is 8 years old ≤ subject ≤ 18 years old, written informed consent from both the subject and the legal guardian is required); If not co-administering β3 agonists/non-selective β-agonists or anticholinergic drugs during the study period, the medication must be discontinued for at least 7 days before the screening period. If continuing to take β3 agonists/non-selective β-agonists or anticholinergic drugs during the study period, the dosage and method of administration must remain unchanged until the study is completed.